|
|
|
|
|
Tirofiban
drug data and news
Tirofiban drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Tirofiban | ||
| Brand Names/Synonyms | AGG; Aggrastat; Tirofiban; Tirofiban [Ban:Inn] | ||
| Indication | For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. When administered intravenously, tirofiban inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. When given according to the recommended regimen, >90% inhibition is attained by the end of the 30-minute infusion. Tirofiban has been recently shown in patients with unstable angina to reduce ischemic events at 48 hours following infusion when compared to standard heparin therapy. | ||
| Mechanism Of Action | Tirofiban is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. Platelet aggregation inhibition is reversible following cessation of the infusion of Tirofiban. | ||
| Tirofiban News (When available) |
| ||
| Dosage Forms | LIQUID; SOLUTION | ||
| Drug_Category | Fibrinolytic Agents; Platelet Aggregation Inhibitors; ATC:B01AC17 | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Tirofiban: AGGRASTAT has been studied on a background of aspirin and heparin. The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 2-butylsulfonylamino-3-[4-[4-(4-piperidyl)butoxy]phenyl]-propanoic acid | ||
| Chemical Formula | C22H36N2O5S | ||
| Molecular Weight | 440.598 g/mol | ||
| Smiles String | CCCCS(=O)(=O)NC(CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O | ||
| Melting Point | Not Available | ||
| Water Solubility | Very slightly soluble | ||
| State | Solid (white to off-white, non-hygroscopic, free-flowing powder) | ||
| LogP/Hphobicity | 3.54 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Metabolism appears to be limited. | ||
| Half Life | 2 hours | ||
| Protein Binding [%] | 65% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.rxlist.com/cgi/generic/tiro.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00304 | ||
| CAS Registry Number | 144494-65-5 | ||
| KEGG Compound ID | C07965 | ||
| PubChem ID | SID:654151 | ||
| PharmGKB ID | PA451698 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2240706 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |